Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- ARDS
- COVID-19
- Pneumonia
- Type
- Observational
- Design
- Observational Model: Case-ControlTime Perspective: Cross-Sectional
Participation Requirements
- Age
- Younger than 125 years
- Gender
- Both males and females
Description
Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against SARS-CoV-2, hydroxychloro...
Several treatments have been used in during the Covid-19 pandemic of 2020. Using patients' registries from several hospitals in Paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against SARS-CoV-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation. Other outcomes of interest include: acute kidney injury, encephalopathy, need for intensive care unit transfers.
Tracking Information
- NCT #
- NCT04365764
- Collaborators
- Centre Hospitalier Intercommunal Robert Ballanger
- Centre Hospitalier Intercommunal Montfermeil-Le Raincy
- CMC Ambroise Paré
- Investigators
- Study Chair: Joe-Elie Salem, MD, PhD APHP
Get Well Soon